1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HLA-independent T cell receptors effectively target low abundance antigens
    Meeting Abstract

    Mansilla-Soto, J.; Eyquem, J.; Haubner, S.; Hamieh, M.; Feucht, J.; Paillon, N.; Zucchetti, A.; Li, Z.; Sjöstrand, M.; Lindenbergh, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (r/mCC): Phase 1b/2 ENGOT-cx8/GOG-3024/ innovaTV 205 study dose-escalation results
    Meeting Abstract

    Monk, B.; Van Gorp, T.; Lorusso, D.; O'Cearbhaill, R. E.; Westermann, A.; Banerjee, S.; Collins, D.; Klat, J.; Madsen, K.; Baurain, J. F.; more...
    International Journal of Gynecological Cancer (2021)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on chromatin remodeling and MAPK activation and is targetable
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Stivala, S.; Brkic, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis
    Meeting Abstract

    Rejeski, K.; Perez, A.; Sesques, P.; Berger, C.; Jentzsch, L.; Mougiakakos, D.; Frölich, L.; Ackermann, J.; Bücklein, V.; Blumenberg, V.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a Single-arm extension
    Meeting Abstract

    Sehn, L. H.; Hess, G.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: Update of MANIFEST phase 2 study
    Meeting Abstract

    Platzbecker, U.; Mascarenhas, J.; Harrison, C.; Patriarca, A.; Devos, T.; Palandri, F.; Rampal, R.; Vannucchi, A.; Mead, A.; Kremyanskaya, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Dreyling, M.; Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Clinical phenotypes of CAR-T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Rejeski, K.; Sesques, P.; Berger, C.; Jentzsch, L.; Mougiakakos, D.; Frölich, L.; Bücklein, V.; Blumenberg, V.; Schmidt, C.; Jallades, L.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome
    Journal Article

    Nakamura, R.; Saber, W.; Martens, M. J.; Ramirez, A.; Scott, B.; Oran, B.; Leifer, E.; Tamari, R.; Mishra, A.; Maziarz, R. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save